Merrimack to use ACD's RNAscope to Evaluate NSCLC Drug Candidate | GenomeWeb

NEW YORK (GenomeWeb) – Advanced Cell Diagnostics today announced that Merrimack Pharmaceuticals will use its RNAscope technology for Merrimack's Phase II clinical trial of its drug candidate for metastatic non-small cell lung cancer. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.